AIM
EBS icon

Advantage Investment Management’s Emergent Biosolutions EBS Stock Holding History

Advantage Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-169
Closed -$6K – 874
2016
Q1 		$6K Buy
+169
New +$5.97K ﹤0.01% 654
2015
Q1 		– Sell
-298
Closed -$8K – 858
2014
Q4 		$8K Buy
+298
New +$7.1K 0.01% 556

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Advantage Investment Management's EBS Position: Q2 2016 in Review

Advantage Investment Management sold out of Emergent Biosolutions (EBS) in Q2 2016, closing a stake of 169 shares — an estimated $6K sold.

Advantage Investment Management first reported a position in EBS in Q4 2014 and held it in 2 quarters. The position peaked at $8K in Q4 2014. 224 funds tracked by Wall St. Rank hold EBS as of Q2 2016.

  • Advantage Investment Management reported no remaining Emergent Biosolutions position as of Q2 2016 after selling out during the quarter.
  • Advantage Investment Management sold 169 Emergent Biosolutions shares in Q2 2016, an estimated $6K.
  • Advantage Investment Management first reported a position in Emergent Biosolutions in Q4 2014 and held it in 2 quarters.
  • Advantage Investment Management's Emergent Biosolutions position peaked at $8K in Q4 2014.
  • 224 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2016.

Based on Advantage Investment Management's 13F filing for Q2 2016, filed 27 Mar 2017.